Dr. Luke Evnin co-founded MPM's asset management business in 1997 to launch MPM's first venture fund and established the San Francisco office for the firm in 1999. Dr. Evnin was at Accel Partners for over seven years including four as a General Partner. He was involved in biopharmaceutical, medical device and healthcare service companies for Accel's funds III, IV and V. Dr. Evnin earned his Ph.D. in the Department of Biochemistry at the University of California-San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University.
Amphivena Therapeutics, Inc.
Costim Pharmaceuticals, Inc.
Enteromedics, Inc. (NASDAQ:ETRM)
Syndax Pharmaceuticals, Inc.
Epic Therapeutics, Inc.
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX)
Idun Pharmaceuticals, Inc.
Intercell AG (VSE:ICLL)
Metabasis Therapeutics, Inc. (NASDAQ:MBRX)
NeuroTherapeutics Pharma, Inc.
Oscient Pharmaceuticals Corp. (NASDAQ:OSCI)
Pacira Pharmaceuticals, Inc.
Signal Pharmaceuticals, Inc.
Sonic Innovations, Inc. (NASDAQ:SNCI)